These results collectively indicated that (i) T-cell lymphoma may be a promising target for VSV therapy, and (ii) that clinical response to systemic VSV therapy may be associated with hepatotoxicity and PK biomarkers including peak viremia and persistence of serum IFNβ. This evidence concerns the gene IFNB1 and T-cell non-Hodgkin lymphoma.